The Consumer Advisory Council will meet on Thursday, April 17, 1997. The meeting, which will be open to public observation, will take place at the Federal Reserve Board's offices in Washington, D.C., in Terrace Room E of the Martin Building. The meeting will begin at 9:00 a.m. and is expected to continue until 4:00 p.m., with a lunch break from 1:00 p.m. until 2:00 p.m. The Martin Building is located on C Street, Northwest, between 20th and 21st Streets in Washington, D.C.
The Council's function is to advise the Board on the exercise of the Board's responsibilities under the Consumer Credit Protection Act and on other matters on which the Board seeks its advice. Time permitting, the Council will discuss the following topics:
Bank Regulatory Issues
The Bank Regulation Committee will discuss the potential effects of bank mergers and acquisitions on local communities; and will also discuss proposed interagency regulations to implement section 109 of the RiegleNeal Interstate Banking and Branching Efficiency Act of 1994, which among other things provide guidance for determining whether a bank is reasonably helping to meet community credit needs served by interstate branches.
Electronic Banking and Electronic Disclosures
The Depository and Delivery Systems, Community Affairs and Housing, and Consumer Credit Committees will discuss recommendations for revisions to consumer regulations such as Regulations DD (Truth in Savings), E (Electronic Fund Transfers), B (Equal Credit Opportunity), and Z (Truth in Lending) to allow required disclosures and documentation to be provided to consumers electronically. The Depository and Delivery Systems Committee will also discuss industry and consumer issues involving electronic and home banking, and a Board report on the application of the Electronic Fund Transfer Act to electronic stored-value products.
Consumer Identifying Information
The Depository and Delivery Systems Committee will discuss findings in a Board report on the availability of consumer identifying information and financial fraud.
Recommendations To Simplify Mortgage Lending Disclosures
The Consumer Credit Committee will discuss possible recommendations for statutory amendments that may be required to simplify, consolidate, and streamline the provisions of Regulations Z (Truth in Lending Act) and X (RESPA) affecting home mortgage lending.
Governor's Report
Report by Federal Reserve Board Member Laurence H. Meyer on economic conditions, recent Board initiatives, and issues of concern, with an opportunity for questions from Council members.
Members Forum
Presentation by individual Council members on the economic conditions present within their industries or local economies.
Committee Reports
Committees will report on plans for 1997; in addition, the Consumer Credit Committee will discuss some issues to be addressed in Federal Reserve Board hearings on home equity lending (which will be held pursuant to the Home Ownership Equity Protection Act of 1994).
Other matters previously considered by the Council or initiated by Council members also may be discussed. Specifically, Mr. Portuese fabricated data in a study of angiotensinconverting enzyme polymorphism and complications from insulin-dependent diabetes mellitus. These fabricated data were included in an abstract that was submitted to the American Diabetes Association in January 1996; however, the abstract was not accepted, presented in public, or published.
In addition, Mr. Portuese fabricated genetic data on lipoprotein lipase polymorphisms as related to diabetes complications and risk factors. These fabricated data were included in tables prepared by Mr. Portuese and presented by him to his doctoral committee in October 1996. None of the fabricated data in question has been published, presented at a scientific meeting, or used in any grant applications.
Mr. Portuese has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning March 25, 1997:
(1) To exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and (2) That any institution that submits an application for PHS support for a research project on which Mr. Portuese's participation is proposed or which uses him in any capacity on PHS supported research must concurrently submit a plan for supervision of his duties. The supervisory plan must be designed to ensure the scientific integrity of Mr. Portuese's research contribution. The institution must submit a copy of the supervisory plan to ORI.
No scientific publications were required to be corrected as part of this Agreement.
FOR FURTHER INFORMATION CONTACT:
Acting 
I. Background
On November 19, 1993, the United States District Court for the District of Minnesota entered judgment against Barry D. Garfinkel for, among other counts, 3 counts of making a false statement in a matter within the jurisdiction of FDA, a Federal felony offense under 18 U.S.C. 1001. The basis for this conviction was Dr. Garfinkel's falsification of reports to conceal his failure to comply with the protocols of a clinical study of the drug Anafranil. Dr. Garfinkel's conviction was affirmed by the Eighth Circuit Court of Appeals on July 13, 1994.
As a result of this conviction, FDA served Dr. Garfinkel by certified mail on February 7, 1995, a letter proposing to issue an order under section 306(a) of the act (21 U.S.C. 335a(a)) permanently debarring him from providing services in any capacity to a person that has an approved or pending drug product application and offering him an opportunity for a hearing on the proposal. The proposal was based on a finding, under section 306(a)(2)(A) and (a)(2)(B) of the act, that Dr. Garfinkel was convicted of a felony under Federal law for conduct relating to the development, approval, and regulation of a drug product. Dr. Garfinkel requested a hearing in a letter dated February 16, 1995. However, Dr. Garfinkel has not submitted any information or analyses to justify a hearing. Dr. Garfinkel's failure to raise any issues of fact constitutes a waiver of his opportunity for a hearing and a waiver of any contentions concerning his debarment (21 CFR 12.22).
II. Findings and Order
Therefore, the Deputy Commissioner for Operations, under section 306(a) of the act and under authority delegated to him (21 CFR 5.20) , finds that Barry D. Garfinkel has been convicted of a felony under Federal law for conduct relating to the development or approval of a drug product and for conduct relating to regulation of a drug product (21 U.S.C. 335a(a)(2)(B)).
As a result of the foregoing finding, Barry D. Garfinkel is permanently debarred from providing services in any capacity to a person with an approved or pending drug product application under sections 505, 507, 512, or 802 of the act (21 U.S.C. 355, 357, 360b, or 382) , or under section 351 of the Public Health Service Act (42 U.S.C. 262), effective April 2, 1997 sections 306(c)(1)(B) and (c)(2)(A)(ii) and 201(dd) of the act (21 U.S.C. 321(dd)). Any person with an approved or pending drug product application who knowingly uses the services of Dr. Garfinkel, in any capacity, during his period of debarment, will be subject to a civil money penalty (section 307(a)(6) of the act (21 U.S.C. 335b(a)(6))). If Dr. Garfinkel, during his period of debarment, provides services in any capacity to a person with an approved or pending drug product application, he will be subject to a civil money penalty (section 307(a)(7) of the act). In addition, FDA will not accept or review any abbreviated new drug applications or abbreviated antibiotic drug applications submitted by or with the assistance of Dr. Garfinkel during his period of debarment.
Dr. Garfinkel may file an application to attempt to terminate his debarment under section 306(d)(4)(A) of the act. Any such application would be reviewed under the criteria and processes set forth in section 306(d)(4)(C) and (d)(4)(D) of the act. Such an application should be identified with Docket No. 94N-0011 and sent to the Dockets Management Branch (address above). All such submissions are to be filed in four copies. The public availability of information in these submissions is governed by 21 CFR 10.20(j). Publicly available submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.
